Use of cytokines in cancer vaccines/immunotherapy: Recent developments improve survival rates for patients with metastatic malignancy

Current Pharmaceutical Design

Volumn 11, Issue 27, 2005, Pages 3511-3530

  Dezfouli, S ^a   Hatzinisirio, I ^a   Ralph, S J ^a  

^a GRIFFITH UNIVERSITY   (Australia)

Author keywords

Cancer vaccines; Cytokines; Immune surveillance; Immunotherapy; Patient survival; Response rates

Indexed keywords

ALPHA INTERFERON; ALPHA1 INTERFERON; ALPHA2B INTERFERON; ANTINEOPLASTIC AGENT; BCG VACCINE; BETA1 INTERFERON; CANCER VACCINE; CANVAXIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOKINE; DACARBAZINE; DENDRITIC CELL VACCINE; FLUOROURACIL; GAMMA INTERFERON; GANGLIOSIDE GM2; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; INTERFERON RECEPTOR; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 2; M VAX; TAMOXIFEN; TUMOR ANTIGEN; TUMOR CELL VACCINE; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE;

ANTIGEN PRESENTING CELL; AUTOTRANSPLANTATION; BLEEDING DISORDER; BRAIN METASTASIS; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CELL BASED GENE THERAPY; CELL FUNCTION; CLINICAL RESEARCH; CLINICAL TRIAL; DISSEMINATED CANCER; DRUG RECEPTOR BINDING; FEBRILE NEUTROPENIA; FLU LIKE SYNDROME; HUMAN; IMMUNOSURVEILLANCE; KIDNEY CARCINOMA; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; META ANALYSIS; NONHUMAN; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SIGNAL TRANSDUCTION; SURVIVAL RATE; SURVIVAL TIME; SYSTEMATIC REVIEW; THROMBOCYTE DISORDER; TREATMENT OUTCOME; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL; WHOLE CELL;

CANCER VACCINES; CYTOKINES; HUMANS; IMMUNOTHERAPY; NEOPLASM METASTASIS; SURVIVAL RATE;

EID: 24944459911     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161205774414574     Document Type: Review

References (175)

1. Burnet FM. Cancer- A Biological Approach. Br Med J 1957; i: 841-7.
2. Burnet FM. The Concept of Immunological Surveillance. Progr Exp Tumor Res 1970; 13: 1-27.
3. Isaacs A, Lindenman J. Virus Interference I. The Interferon. Proc R Soc Med 1957; 147: 258-7.
4. Morton D, Eilber FR, Malmgren RA, Wood WC. Immunological factors which influence response to immunotherapy in malignant melanoma. Surgery 1970; 68: 158-64.
5. Eilber FR, Morton DL. Impaired immunologic reactivity and recurrence following cancer surgery. Cancer 1970; 25: 362-67.
6. Vanky R, Klein E, Stjernsward J, Nilsonne U. Cellular immunity against tumor-associated antigens in humans: lymphocyte stimulation and skin reaction. Int J Cancer 1974; 14: 277-88.
7. Cochran AJ, Mackie RM, Grant RM, Ross CE, Connell MD, Sandilands G, et al. An examination of the immunology of cancer patients. Int J Cancer 1976; 18: 298-309.
8. Cochran AJ, Buyse ME, Lejeune FJ, Macher E, Revuz J, Rumke P. Adjuvant reactivity predicts survival in patients with "high-risk" primary malignant melanoma treated with systemic BCG. EORTC Malignant Melanoma Cooperative Group Writing Committee. Int J Cancer 1981; 28: 543-50.
9. Camacho ES, Pinsky CM, Braun DW Jr, Golbey RB, Fortner JG, Wanebo HJ, et al. DNCB reactivity and prognosis in 419 patients with malignant melanoma. Cancer 1981; 47: 2446-50.
10. Lee ET, Ishmael DR, Bottomley RH, Murray JL. An analysis of skin tests and their relationship to recurrence and survival in stage III and stage IV melanoma patients. Cancer 1982; 49: 2336-41.
11. Saltz J, Buckley CE 3rd, Cox E, Seigler HF. The prognostic significance of recall antigen testing in melanoma patients. Am J Med Sci 1987; 294: 287-93.
12. Bystryn JC, Oratz R, Roses D, Harris M, Henn M, Lew R. Relationship between immune response to melanoma vaccine immunization and clinical outcome in stage II malignant melanoma. Cancer 1992; 69: 1157-64.
13. Cartei G, Sala PG, Sanzari M, Ceschia V, Clocchiatti L, Sibau A, et al. Reduced lymphocyte subpopulations in patients with advanced or disseminated melanoma. J Am Acad Dermatol 1993; 28(5 Pt1): 738-44.
14. Czarnecki D, Zalcberg J, Kulinskaya E, Kay T. Impaired cell-mediated immunity of apparently normal patients who had multiple skin cancers. Cancer 1995; 76: 228-31.
15. Henz BM, Macher E, Brocker EB, Suciu S, Steerenberg PA, Jung E, et al. Prognostic value of tuberculin and BCG immunoreactivity in stage I high-risk malignant melanoma (EORTC protocol 18781). Dermatology 1996; 193: 105-9.
16. Hsueh EC, Gupta RK, Qi K, Morton DL. Correlation of specific immune responses with survival in melanoma patients with distant metastases receiving polyvalent melanoma cell vaccine. J Clin Oncol 1998; 16: 2913-20.
17. Crawford J, Foote M, Morstyn G. Hematopoietic growth factors in cancer chemotherapy. Cancer Chemother Biol Response Modif 1999; 18: 250-67.
18. Nawrocki S, Wysocki PJ, Mackiewicz A. Genetically modified tumour vaccines: an obstacle race to break host tolerance to cancer. Expert Opin Biol Ther 2001; 1: 193-204.
19. Tirapu I, Rodriguez-Calvillo M, Qian C, Duarte M, Smerdou C, Palencia B, et al. Cytokine gene transfer into dendritic cells for cancer treatment. Curr Gene Ther 2002; 2: 79-89.
20. Morse MA, Lyerly HK. DNA and RNA modified dendritic cell vaccines. World J Surg 2002; 26: 819-25.
21. Foss FM. Immunologic mechanisms of antitumor activity. Semin Oncol 2002; 29(3 Suppl 7): 5-11.
22. Fay JW. Hematopoietic growth factors, dendritic cell biology, and vaccine therapy of cancer. Curr Opin Hematol 2002; 9: 202-6.
23. Reinhard G, Marten A, Kiske SM, Feil F, Bieber T, Schmidt-Wolf IG. Generation of dendritic cell-based vaccines for cancer therapy. Br J Cancer 2002; 86: 1529-33.
24. Parmiani G, Castellie C, Dalerba P, Mortarini R, Rivoltini L, Marincola FM, et al. Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going? J Natl Cancer Inst 2002; 94: 805-18.
25. Weber J. Peptide vaccines for cancer. Cancer Invest 2002; 20: 208-21.
26. Buteau C, Markovic SN, Celis E. Challenges in the development of effective peptide vaccines for cancer. Mayo Clin Proc 2002; 77: 339-49.
27. Rosenberg SA. Progress in the development of immunotherapy for the treatment of patients with cancer. J Internal Med 2001; 250: 462-75.
28. Jager E, Jager D, Knuth, A. Antigen-specific immunotherapy and cancer vaccines. Curr Opin Immunol 2002; 14: 178-82.
29. Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD. How cells respond to interferons. Annu Rev Biochem 1998; 67: 227-64.
30. Gray RJ, Pockaj BA, Kirkwood JM. An update on adjuvant interferon for melanoma. Cancer Control 2002; 9: 16-21.
31. Lens MB, Dawes M. Interferon alfa therapy for malignant melanoma: a systematic review of randomized controlled trials. J Clin Oncol 2002; 20: 1818-25.
32. Kirkwood JM, Ibrahim JG, Sondak VK, Ernstoff MS, Ross M. Interferon alfa-2a for melanoma metastases. Lancet 2002; 359: 978-9.
33. Belardelli F, Ferrantini M, Proietti E, Kirkwood JM. Interferon-alpha in tumor immunity and immunotherapy. Cytokine Growth Factor Rev 2002; 13: 119-34.
34. Atkins MA, Shet A, Sosman JA. Interleukin-2: Clinical Applications. Melanoma. In: Rosenberg SA Ed, Principles and Practice of the Biologic Therapy of Cancer, Philadelphia, Lippincott Williams and Wilkins 2000; Chpt 3.2: 50-72.
35. Atkins MA. Interleukin-2: Clinical Applications. Semin Oncol 2002; 29(3 suppl 7): 12-17.
36. Yang J C-Y. Interleukin-2: Clinical Applications. Renal Cell Carcinoma. In: Rosenberg SA Ed, Principles and Practice of the Biologic Therapy of Cancer, Philadelphia, Lippincott Williams and Wilkins 2000; Chpt 3.3: 73-82.
37. Gitlitz BJ, Hoffman DM, Moldawer N, Belldegrun A, Figlin A. Treatment of metastatic renal cell carcinoma with high-dose bolus interleukin-2 in a non-intensive care unit: an analysis of 124 consecutively treated patients. Cancer J 2001; 7: 112-20.
38. Eton O, Rosenblum MG, Legha SS, Zhang W, Jo East M, Bedikian A, et al. Phase I trial of subcutaneous recombinant human interleukin-2 in patients with metastatic melanoma. Cancer 2002; 95: 127-34.
39. Rosenberg SA, Lotze MT, Yang JC, Linehan WM, Seipp C, Calabro S, et al. Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer. J Clin Oncol 1989; 7: 1863-74.
40. Nathan PD, Eisen TG. The biological treatment of renal-cell carcinoma and melanoma. Lancet Oncol 2002; 3: 89-96.
41. Keilholz U, Scheibenbogen C, Tilgen W, Bergmann L, Weidmann E, Seither E, et al. Interferon-alpha and interleukin-2 in the treatment of metastatic melanoma. Comparison of two phase II trials. Cancer 1993; 72: 607-14.
42. Malaguarnera M, Ferlito L, Gulizia G, Di Fazio I, Pistone G. Use of interleukin-2 in advanced renal carcinoma: meta-analysis and review of the literature. Eur J Clin Pharmacol 2001; 57: 267-73.
43. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002; 298: 850-4.
44. Serrone L, Zeuli M, Sega FM, Cognetti F. Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview. J Exp Clin Cancer 2000; 19: 21-34.
45. Young AM, Marsden J, Goodman A, Burton A, Dunn JA. Prospective randomized comparison of dacarbazine (DTIC) versus DTIC plus interferon-alpha (IFN-alpha) in metastatic melanoma. Clin Oncol 2001; 13: 458-65.
46. Huncharek M, Caubet JF, McGarry R. Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: a meta-analysis of 3273 patients from 20 randomized trials. Melanoma Res 2001; 11: 75-81.
47. Sun W, Schuchter LM. Metastatic melanoma. Curr Treat Options Oncol 2001; 2: 193-204.
48. Legha SS, Ring S, Eton O, Bedikian A, Plager C, Papadopoulos N. Development and results of biochemotherapy in metastatic melanoma: the University of Texas M.D. Anderson Cancer Center experience. Cancer J Sci Am 1997; 3 Suppl 1: S7-8.
49. Legha SS, Ring S, Eton O, Bedikian A, Buzaid AC, Plager C, et al. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma. J Clin Oncol 1998; 16: 1752-9.
50. McDermott DF, Mier JW, Lawrence DP, van den Brink MR, Clancy MA, Rubin KM, et al. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon alpha-2B in patients with metastatic melanoma. Clin Cancer Res 2000; 6: 2201-8.
51. Buzaid AC, Colome M, Bedikian A, Eton O, Legha SS, Papadopoulos N, et al. Phase II study of neoadjuvant concurrent biochemotherapy in melanoma patients with local-regional metastases. Melanoma Res 1998; 8: 549-56.
52. O'Day SJ, Gammon G, Boasberg PD, Martin MA, Kristedja TS, Guo M, et al. Advantages of concurrent biochemotherapy modified by decrescendo interleukin-2, granulocyte colony-stimulating factor, and tamoxifen for patients with metastatic melanoma. J Clin Oncol 1999; 17: 2752-61.
53. O'Day SJ, Kim CJ, Reintgen DS. Metastatic melanoma: chemotherapy to biochemotherapy. Cancer Control 2002; 9: 31-8.
54. O'Day SJ, Boasberg PD, Piro L, Kristedja TS, Wang HJ, Martin M, et al. Maintenance biotherapy for metastatic melanoma with interleukin-2 and granulocyte macrophage-colony stimulating factor improves survival for patients responding to induction concurrent biochemotherapy. Clin Cancer Res 2002; 8: 2775-81.
55. Flaherty LE, Atkins M, Sosman J, Weiss G, Clark JI, Margolin K, et al. Outpatient biochemotherapy with interleukin-2 and interferon alfa-2b in patients with metastatic malignant melanoma: results of two phase II cytokine working group trials. J Clin Oncol 2001; 19: 3194-202.
56. Ridolfi R, Chiarion-Sileni V, Guida M, Romanini A, Labianca R, Freschi A, et al. Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trial. J Clin Oncol 2002; 20: 1600-7.
57. Eton O, Legha SS, Bedikian AY, Lee JJ, Buzaid AC, Hodges C, et al. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J Clin Oncol 2002; 20: 2045-52.
58. Atkins MB, Lee S, Flaherty LE, Sosman JA, Sondak VK, Kirkwood JM. A prospective randomized phase III trial of concurrent biochemotherapy (BCT) with cisplatin, vinblastine, dacarbazine (CVD), IL-2 and interferon alpha-2b (IFN) versus CVD alone in patients with metastatic melanoma (E3695): An ECOG-coordinated intergroup trial. Proc Am Soc Clin Oncol 2003; 22; page 708, abstr. 2847.
59. Keilholz U, Punt CJ, Gore M, Suciu S, Kruit W, Patel P, et al. Dacarbazine, cisplatin and IFN-α2b with or without IL-2 in advanced melanoma: Final analysis of EORTC randomized phase III trial 18951. Proc Am Soc Clin Oncol 2003; 22: page 708, abstr. 2848.
60. Schmittel A, Proebstle T, Engenhart-Cabillic R, Scheibenbogen C, Geueke AM, Thiel E, et al. Brain metastases following interleukin-2 plus interferon-alpha-2a therapy: a follow-up study in 94 stage IV melanoma patients. Eur J Cancer 2003; 39: 476-80.
61. Boasberg PD, O'Day SJ, Kristedja TS, Martin M, Wang H, Deck R, et al. Biochemotherapy for metastatic melanoma with limited central nervous system involvement. Oncology 2003; 64: 328-35.
62. Chapman PB, Einhorn LH, Meyers ML, Saxman S, Destro AN, Panageas K, et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 1999; 17: 2745-51.
63. Middleton MR, Lorigan P, Owen J, Ashcroft L, Lee SM, Harper P, et al. A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma. Br J Cancer 2000; 82: 1158-62.
64. Atzpodien J, Neuber K, Kamanabrou D, Fluck M, Brocker EB, Neumann C, et al. Combination chemotherapy with or without s.c. IL-2 and IFN-alpha: results of a prospectively randomized trial of the Cooperative Advanced Malignant Melanoma Chemoimmunotherapy Group (ACIMM). Br J Cancer 2002; 86: 179-84.
65. Schomburg A, Kirchner H, Fenner M, Menzel T, Poliwoda H, Atzpodien J. Lack of therapeutic efficacy of tamoxifen in advanced renal cell carcinoma. Eur J Cancer 1993; 29A: 737-40.
66. Atzpodien J, Lopez Hanninen E, Kirchner H, Franzke A, Korfer A, Volkenandt M, et al. Chemoimmunotherapy of advanced malignant melanoma: sequential administration of subcutaneous interleukin-2 and interferon-alpha after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, carmustine and tamoxifen. Eur J Cancer 1995; 31A: 876-81.
67. Thompson JA, Gold PJ, Markowitz DR, Byrd DR, Lindgren CG, Fefer A. Updated analysis of an outpatient chemoimmunotherapy regimen for treating metastatic melanoma. Cancer J Sci Am 1997; 3 Suppl 1: S29-34.
68. Hoffmann R, Muller I, Neuber K, Lassmann S, Buer J, Probst M, et al. Risk and outcome in metastatic malignant melanoma patients receiving DTIC, cisplatin, BCNU and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha2a. Br J Cancer 1998; 78: 1076-80.
69. Richards JM, Gale D, Mehta N, Lestingi T. Combination of chemotherapy with interleukin-2 and interferon alfa for the treatment of metastatic melanoma. J Clin Oncol 1999; 17: 651-7.
70. Johnston SR, Constenla DO, Moore J, Atkinson H, A'Hern RP, Dadian G, et al. Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma. Br J Cancer 1998; 77: 1280-6.
71. Glaspy JA. Therapeutic options in the management of renal cell carcinoma. Semin Oncol 2002; 29(3 Suppl 7): 41-6.
72. Atzpodien J, Kirchner H, Hanninen EL, Deckert M, Fenner M, Poliwoda H. Interleukin-2 in combination with interferon-alpha and 5-fluorouracil for metastatic renal cell cancer. Eur J Cancer 1993; 29A Suppl 5: S6-8.
73. Atzpodien J, Kirchner H, Illiger HJ, Metzner B, Ukena D, Schott H, et al. IL-2 in combination with IFN-alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial. Br J Cancer 2001; 85: 1130-6.
74. Lopez Hanninen E, Kirchner H, Atzpodien J. Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients. J Urol 1996; 155: 19-25.
75. Hofmockel G, Langer W, Theiss M, Gruss A, Frohmuller HG. Immunochemotherapy for metastatic renal cell carcinoma using a regimen of interleukin-2, interferon-alpha and 5-fluorouracil. J Urol 1996; 156: 18-21.
76. Allen MJ, Vaughan M, Webb A, Johnston S, Savage P, Eisen T, et al. Protracted venous infusion 5-fluorouracil in combination with subcutaneous interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer: a phase II study. Br J Cancer 2000; 83: 980-5.
77. van Herpen CM, Jansen RL, Kruit WH, Hoekman K, Groenewegen G, Osanto S, et al. Immunochemotherapy with interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study. Dutch Immunotherapy Working Party. Br J Cancer 2000; 82: 772-6.
78. Tourani JM, Pfister C, Berdah JF, Benhammouda A, Salze P, Monnier A, et al. Outpatient treatment with subcutaneous interleukin-2 and interferon alfa administration in combination with fluorouracil in patients with metastatic renal cell carcinoma: results of a sequential nonrandomized phase II study. Subcutaneous Administration Propeukin Program Cooperative Group. J Clin Oncol 1998; 16: 2505-13.
79. Joffe JK, Banks RE, Forbes MA, Hallam S, Jenkins A, Patel PM, et al. A phase II study of interferon-alpha, interleukin-2 and 5-fluorouracil in advanced renal carcinoma: clinical data and laboratory evidence of protease activation. Br J Urol 1996; 77: 638-49.
80. Dutcher JP, Atkins M, Fisher R, Weiss G, Margolin K, Aronson F, et al. Interleukin-2-based therapy for metastatic renal cell cancer: the Cytokine Working Group experience, 1989-1997. Cancer J Sci Am 1997; 3 Suppl. 1: S73-8.
81. Dutcher JP, Logan T, Gordon M, Sosman J, Weiss G, Margolin K, et al. Phase II trial of interleukin 2, interferon alpha, and 5-fluorouracil in metastatic renal cell cancer: a cytokine working group study. Clin Cancer Res 2000; 6: 3442-50.
82. Hofmockel G, Bassukas ID, Wittmann A, Dammrich J. Is the expression of multidrug resistance gene product a prognostic indicator for the clinical outcome of patients with renal cancer? Br J Urol 1997; 80: 11-17.
83. Lens MB, Eisen TG. Systemic chemotherapy in the treatment of malignant melanoma. Expert Opin Pharmacother 2003; 4: 2205-11.
84. Joffe JK, Patel PM, Banks RE, Selby PJ. Cytokines in combination with chemotherapy for advanced renal carcinoma--the importance of patient selection. Cancer Biother Radiopharm 1996; 11: 309-13.
85. Figlin R, Gitlitz B, Franklin J, Dorey F, Moldawer N, Rausch J, et al. Interleukin-2-based immunotherapy for the treatment of metastatic renal cell carcinoma: an analysis of 203 consecutively treated patients. Cancer J Sci Am 1997; 3 Suppl. 1: S92-7.
86. Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001; 345: 1655-9.
87. Clark JI, Kuzel TM, Lestingi TM, Fisher SG, Sorokin P, Martone B, et al. A multi-institutional phase II trial of a novel inpatient schedule of continuous interleukin-2 with interferon alpha-2b in advanced renal cell carcinoma: major durable responses in a less highly selected patient population. Ann Oncol 2002; 13: 606-13.
88. Ellem KA, O'Rourke MG, Johnson GR, Parry G, Misko IS, Schmidt CW, et al. A case report: immune responses and clinical course of the first human use of granulocyte/macrophage-colony-stimulating-factor-transduced autologous melanoma cells for immunotherapy. Cancer Immunol Immunother 1997; 44: 10-20.
89. Keilholz U, Weber J, Finke JH, Gabrilovich DI, Kast WM, Disis ML, et al. Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J Immunother 2002; 25: 97-138.
90. Dranoff G. Interpreting cancer vaccine clinical trials. J Gene Med 1999; 1: 80-3.
91. Waanders GA, Rimoldi D, Lienard D, Carrel S, Lejeune F, Dietrich PY, et al. Melanoma-reactive human cytotoxic T lymphocytes derived from skin biopsies of delayed-type hypersensitivity reactions induced by injection of an autologous melanoma cell line. Clin Cancer Res 1997; 3: 685-96.
92. Klein J, Sato A. The HLA system. First of two parts. N Engl J Med 2000; 343: 702-9.
93. Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol 2000; 74: 181-273.
94. Saleh FH, Crotty KA, Hersey P, Menzies SW. Primary melanoma tumour regression associated with an immune response to the tumour-associated antigen melan-A/MART-1. Int J Cancer 2001; 94: 551-7.
95. Jager E, Jager D, Knuth A. Clinical cancer vaccine trials. Curr Opin Immunol 2002; 14: 178-82.
96. Seiter S, Monsurro V, Nielsen MB, Wang E, Provenzano M, Wunderlich JR, et al. Frequency of MART-1/MelanA and gp100/PMel17-specific T cells in tumor metastases and cultured tumor-infiltrating lymphocytes. J Immunother 2002; 25: 252-63.
97. Svane IM, Boesen M, Engel AM. The role of cytotoxic T-lymphocytes in the prevention and immune surveillance of tumors--lessons from normal and immunodeficient mice. Med Oncol 1999; 16: 223-38.
98. Smyth MJ, Trapani JA. Lymphocyte-mediated immunosurveillance of epithelial cancers? Trends Immunol 2001; 22: 409-11.
99. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993; 90: 3539-43.
100. Soiffer R, Lynch T, Mihm M, Jung K, Rhuda C, Schmollinger JC, et al. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc Natl Acad Sci USA 1998; 95: 13141-6.
101. Dummer R. GVAX (Cell Genesys). Curr Opin Investig Drugs 2001; 2: 844-8.
102. Simons J, Nelson W, Nemunaitis J, Centeno A, Dula E, Urba W, et al. Phase II trials of a GM-CSF gene-transduced prostate cancer cell line vaccine (GVAX) in hormone refractory prostate cancer. Proc Am Soc Clin Oncol 2002; 21: Abstr. 729.
103. Morton DL, Foshag LJ, Hoon DS, Nizze JA, Famatiga E, Wanek LA, et al. Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann Surg 1992; 216: 463-82.
104. Hsueh EC, Nathanson L, Foshag LJ, Essner R, Nizze JA, Stern SL, et al. Active specific immunotherapy with polyvalent melanoma cell vaccine for patients with in-transit melanoma metastases. Cancer 1999; 85; 2160-9.
105. Hsueh EC, Essner R, Foshag LJ, Ye W, Morton DL. Active immunotherapy by reinduction with a polyvalent allogeneic cell vaccine correlates with improved survival in recurrent metastatic melanoma. Ann Surg Oncol 2002; 9: 486-92.
106. DiFronzo LA, Gupta RK, Essner R, Foshag LJ, O'Day SJ, Wanek LA, et al. Enhanced humoral immune response correlates with improved disease-free and overall survival in American Joint Committee on Cancer stage II melanoma patients receiving adjuvant polyvalent vaccine. J Clin Oncol 2002; 20: 3242-48.
107. Barth A, Hoon DS, Foshag LJ, Nizze JA, Famatiga E, Okun E, et al. Polyvalent melanoma cell vaccine induces delayed-type hypersensitivity and in vitro cellular immune response. Cancer Res 1994; 54: 3342-5.
108. Morton DL, Hsueh EC, Essner R, Foshag LJ, O'Day SJ, Bilchik A, et al. Prolonged survival of patients receiving active immunotherapy with Canvaxin therapeutic polyvalent vaccine after complete resection of melanoma metastatic to regional lymph nodes. Ann Surg 2002; 236: 438-49.
109. Berd D. M-Vax: an autologous, hapten-modified vaccine for human cancer. Expert Opin Biol Ther 2002; 2: 335-42.
110. Berd D, Sato T, Mastrangelo MJ. Effect of the dose and composition of an autologous hapten-modified melanoma vaccine on the development of delayed-type hypersensitivity responses. Cancer Immunol Immunother 2002; 51: 320-6.
111. Lotem M, Peretz T, Drize O, Gimmon Z, Ad El D, Weitzen R, et al. Autologous cell vaccine as a post operative adjuvant treatment for high-risk melanoma patients (AJCC stages III and IV). The new American Joint Committee on Cancer. Br J Cancer 2002; 86: 1534-9.
112. Dillman RO, Beutel LD, Barth NM, de Leon C, O'Connor AA, DePriest C, et al. Irradiated cells from autologous tumor cell lines as patient-specific vaccine therapy in 125 patients with metastatic cancer: induction of delayed-type hypersensitivity to autologous tumor is associated with improved survival. Cancer Biother Radiopharm 2002; 17: 51-66.
113. Hersey P. Vaccinia viral lysates in treatment of melanoma. In: Mitchell MS Ed, Biological Approaches to Cancer Treatment. Biomodulation. New York, McGraw-Hill Inc. 1993; Chpt 13: 302-25.
114. Kim EM, Sivanandham M, Stavropoulos CI, Bartolucci AA, Wallack MK. Overview analysis of adjuvant therapies for melanoma--a special reference to results from vaccinia melanoma oncolysate adjuvant therapy trials. Surg Oncol 2001; 10: 53-9.
115. Hersey P, Coates AS, McCarthy WH, Thompson JF, Sillar RW, McLeod Ret, al. Adjuvant immunotherapy of patients with high-risk melanoma using vaccinia viral lysates of melanoma: results of a randomized trial. J Clin Oncol 2002; 20: 4181-90.
116. Mitchell MS. Acctive specific immunotherapy of cancer: therapeutic vaccines ("theraccines") for the treatment of disseminated malignancies. In: Mitchell MS Ed, Biological Approaches to Cancer Treatment. Biomodulation. New York, McGraw-Hill Inc., 1993;~ Chpt 14: 326-52.
117. Mitchell MS. Perspective on allogeneic melanoma lysates in active specific immunotherapy. Semin Oncol 1998; 25: 623-35.
118. Mitchell MS. Cancer vaccines, a critical review--Part I. Curr Opin Investig Drugs 2002; 3: 140-9.
119. Mitchell MS, Darrah D, Stevenson L. Therapy of melanoma with allogeneic melanoma lysates alone or with interferon-alfa. Cancer Invest 2002; 20: 759-68.
120. Sosman JA, Unger JM, Liu PY, Flaherty LE, Park MS, Kempf RA, et al. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome. J Clin Oncol 2002; 20: 2067-75.
121. Schirrmacher V, von Hoegen P. Importance of tumor cell membrane integrity and viability for cytotoxic T lymphocyte activation by cancer vaccines. Vaccine Res 1993; 2; 183-96.
122. Guilloux Y, Bai XF, Liu X, Zheng P, Liu Y. Optimal induction of effector but not memory antitumor cytotoxic T lymphocytes involves direct antigen presentation by the tumor cells. Cancer Res 2001; 61: 1107-12.
123. Salmon SE, Durie BG, Young L, Liu RM, Trown PW, Stebbing N. Effects of cloned human leukocyte interferons in the human tumor stem cell assay. J Clin Oncol 1983; 1; 217-25.
124. Schiller JH, Willson JK, Bittner G, Wolberg WH, Hawkins MJ, Borden EC. Antiproliferative effects of interferons on human melanoma cells in the human tumor colony-forming assay. J Interferon Res 1986; 6; 615-25.
125. Salmon SE. Human tumor colony assay and chemosensitivity testing. Cancer Treat Rep 1984; 68; 117-25.
126. Meyskens FL Jr, Loescher L, Moon TE, Takasugi B, Salmon SE. Relation of in vitro colony survival to clinical response in a prospective trial of single-agent chemotherapy for metastatic melanoma. J Clin Oncol 1984; 2: 1223-28.
127. Ross DT, Scherf U, Eisen MB, Perou CM, Rees C, Spellman P, et al. Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet 2000; 24; 227-35.
128. Perou CM, Jeffrey SS, van de Rijn M, Rees CA, Eisen MB, Ross DT, et al. Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc Natl Acad Sci USA 1999; 96: 9212-17.
129. Certa U, Seiler M, Padovan E, Spagnoli GC. High density oligonucleotide array analysis of interferon-alpha2a sensitivity and transcriptional response in melanoma cells. Br J Cancer 2001; 85: 107-14.
130. Certa U, Seiler M, Padovan E, Spagnoli GC. Interferon-a sensitivity in melanoma cells: detection of potential response marker genes. Recent Results Cancer Res 2002; 160: 85-91.
131. Johns TG, Mackay IR, Callister KA, Hertzog PJ, Devenish RJ, Linnane AW. Antiproliferative potencies of interferons on melanoma cell lines and xenografts: higher efficacy of interferon beta. J Natl Cancer Inst 1992; 84; 1185-90.
132. Wines BD, Choe CC, Hatzinisiriou I, Devenish RJ, Linnane AW, Ralph SJ. A colourimetric dye assay to detect anti-viral activity of interferons: sensitivity for measuring cellular responsiveness to interferons. Biochem Mol Biol Int 1993; 31; 1111-20.
133. Ralph SJ, Wines BD, Payne MJ, Grubb D, Hatzinisiriou I, Linnane AW, et al. Resistance of melanoma cell lines to interferons correlates with reduction of IFN-induced tyrosine phosphorylation. Induction of the anti-viral state by IFN is prevented by tyrosine kinase inhibitors. J Immunol 1995; 154; 2248-56.
134. Wong LH, Krauer KG, Hatzinisiriou I, Estcourt MJ, Hersey P, Tam ND, et al. Interferon-resistant human melanoma cells are deficient in ISGF3 components, STAT1, STAT2, and p48-ISGF3gamma. J Biol Chem 1997; 272: 28779-85.
135. Wong LH, Hatzinisiriou I, Devenish RJ, Ralph SJ. IFN-gamma priming up-regulates IFN-stimulated gene factor 3 (ISGF3) components, augmenting responsiveness of IFN-resistant melanoma cells to type I IFNs. J Immunol 1998; 160: 5475-84.
136. Linge C, Gewert D, Rossmann C, Bishop JA, Crowe JS. Interferon system defects in human malignant melanoma. Cancer Res 1995; 55: 4099-104.
137. Pansky A, Hildebrand P, Fasler-Kan E, Baselgia L, Ketterer S, Beglinger C, et al. Defective Jak-STAT signal transduction pathway in melanoma cells resistant to growth inhibition by interferon-alpha. Int J Cancer 2000; 85: 720-5.
138. Chawla-Sarkar M, Leaman DW, Jacobs BS, Tuthill RJ, Chatterjee-Kishore M, Stark GR, et al. Resistance to interferons in melanoma cells does not correlate with the expression or activation of signal transducer and activator of transcription 1 (Stat1). J Interferon Cytokine Res 2002; 22: 603-13.
139. Kaplan DH, Shankaran V, Dighe AS, Stockert E, Aguet M, Old LJ, et al. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci USA 1998; 95; 7556-61.
140. Sun WH, Pabon C, Alsayed Y, Huang PP, Jandeska S, Uddin S, et al. Interferon-alpha resistance in a cutaneous T-cell lymphoma cell line is associated with lack of STAT1 expression. Blood 1998; 91; 570-6.
141. Abril E, Real LM, Serrano A, Jimenez P, Garcia A, Canton J, et al. Unresponsiveness to interferon associated with STAT1 protein deficiency in a gastric adenocarcinoma cell line. Cancer Immunol Immunother 1998; 47: 113-20.
142. Brinckmann A, Axer S, Jakschies D, Dallmann I, Grosse J, Patzelt T, et al. Interferon-alpha resistance in renal carcinoma cells is associated with defective induction of signal transducer and activator of transcription 1 which can be restored by a supernatant of phorbol 12-myristate 13-acetate stimulated peripheral blood mononuclear cells. Br J Cancer 2002; 86; 449-55.
143. Colamonici OR, Domanski P, Platanias LC, Diaz MO. Correlation between interferon (IFN) alpha resistance and deletion of the IFN alpha/beta genes in acute leukemia cell lines suggests selection against the IFN system. Blood 1992; 80: 744-9.
144. Landolfo S, Guarini A, Riera L, Gariglio M, Gribaudo G, Cignetti A, et al. Chronic myeloid leukemia cells resistant to interferon-alpha lack STAT1 expression. Hematol J 2000; 1: 7-14.
145. Kolla V, Lindner DJ, Xiao W, Borden EC, Kalvakolanu DV. Modulation of interferon (IFN)-inducible gene expression by retinoic acid. Up-regulation of STAT1 protein in IFN-unresponsive cells. J Biol Chem 1996; 271: 10508-14.
146. Kolla V, Weihua X, Kalvakolanu DV. Modulation of interferon action by retinoids. Induction of murine STAT1 gene expression by retinoic acid. J Biol Chem 1997; 272: 9742-8.
147. Einhorn S, Grander D. Why do so many cancer patients fail to respond to interferon therapy? J Interferon Cytokine Res 1996; 16: 275-81.
148. Lehtonen A, Matikainen S, Julkunen I. Interferons up-regulate STAT1, STAT2, and IRF family transcription factor gene expression in human peripheral blood mononuclear cells and macrophages. J Immunol 1997; 159: 794-803.
149. Sims SH, Cha Y, Romine MF, Gao PQ, Gottlieb K, Deisseroth AB. A novel interferon-inducible domain: structural and functional analysis of the human interferon regulatory factor 1 gene promoter. Mol Cell Biol 1993; 13: 690-702.
150. Pine R. Convergence of TNFalpha and IFNgamma signalling pathways through synergistic induction of IRF-1/ISGF-2 is mediated by a composite GAS/kappaB promoter element. Nucleic Acids Res 1997; 25: 4346-54.
151. Wong LH, Sim H, Chatterjee-Kishore M, Hatzinisiriou I, Devenish RJ, Stark G, et al. Isolation and characterization of a human STAT1 gene regulatory element. Inducibility by interferon (IFN) types I and II and role of IFN regulatory factor-1. J Biol Chem 2002; 277; 19408-17.
152. Lengyel P. Tumor-suppressor genes: news about the interferon connection. Proc Natl Acad Sci USA 1993; 90: 5893-5.
153. Dighe AS, Richards E, Old LJ, Schreiber RD. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. Immunity 1994; 1: 447-56.
154. Doherty GM, Tsung K, McCluskey B, Norton JA. Endogenous interferon-gamma acts directly on tumor cells in vivo to suppress growth. J Surg Res 1996; 64: 68-74.
155. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001; 410: 1107-11.
156. Min W, Pober JS, Johnson DR. Kinetically coordinated induction of TAP1 and HLA class I by IFN-gamma: the rapid induction of TAP1 by IFN-gamma is mediated by Stat1 alpha. J Immunol 1996; 156; 3174-83.
157. Chatterjee-Kishore M, Kishore R, Hicklin DJ, Marincola FM, Ferrone S. Different requirements for signal transducer and activator of transcription 1alpha and interferon regulatory factor 1 in the regulation of low molecular mass polypeptide 2 and transporter associated with antigen processing 1 gene expression. J Biol Chem 1998; 273: 16177-83.
158. Cramer LA, Nelson SL, Klemsz MJ. Synergistic induction of the Tap-1 gene by IFN-gamma and lipopolysaccharide in macrophages is regulated by STAT1. J Immunol 2000; 165: 3190-7.
159. Arons E, Kunin V, Schechter C, Ehrlich R. Organization and functional analysis of the mouse transporter associated with antigen processing 2 promoter. J Immunol 2001; 166: 3942-51.
160. Guo Y, Yang T, Liu X, Lu S, Wen J, Durbin JE, et al. Cis elements for transporter associated with antigen-processing-2 transcription: two new promoters and an essential role of the IFN response factor binding element in IFN-gamma-mediated activation of the transcription initiator. Int Immunol 2002; 14; 189-200.
161. Kaklamanis L, Leek R, Koukourakis M, Gatter KC, Harris AL. Loss of transporter in antigen processing 1 transport protein and major histocompatibility complex class I molecules in metastatic versus primary breast cancer. Cancer Res 1995; 55: 5191-94.
162. Vitale M, Rezzani R, Rodella L, Zauli G, Grigolato P, Cadei M, et al. HLA class I antigen and transporter associated with antigen processing (TAP1 and TAP2) down-regulation in high-grade primary breast carcinoma lesions. Cancer Res 1998; 58: 737-42.
163. Widschwendter A, Tonko-Geymayer S, Welte T, Daxenbichler G, Marth C, Doppler W. Prognostic significance of signal transducer and activator of transcription 1 activation in breast cancer. Clin Cancer Res 2002; 8: 3065-74.
164. Qin Z, Harders C, Cao X, Huber C, Blankenstein T, Seliger B. Increased tumorigenicity, but unchanged immunogenicity, of transporter for antigen presentation 1-deficient tumors. Cancer Res 2002; 62: 2856-60.
165. Johnsen AK, Templeton DJ, Sy M-S, Harding CV. Deficiency of transporter for antigen presentation (TAP) in tumor cells allows evasion of immune surveillance and increases tumorigenesis. J Immunol 1999; 163: 4224-31.
166. Kageshita T, Hirai S, Ono T, Hicklin DJ, Ferrone S. Down-regulation of HLA class I antigen-processing molecules in malignant melanoma: association with disease progression. Am J Pathol 1999; 154: 745-54.
167. Ikeda H, Old LJ, Schreiber RD. The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev 2002; 13: 95-109.
168. Saleh FH, Crotty KA, Hersey P, Menzies SW, Rahman W. Autonomous histopathological regression of primary tumours associated with specific immune responses to cancer antigens. J Pathol 2003; 200: 383-95.
169. Khong HT, Restifo NP. Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nature Immunol 2002; 3: 999-1005.
170. Levitsky HI. When magic bullets miss their mark. Blood 2001; 97: 833.
171. Dezfouli S, Hatzinisiriou I, Ralph SJ. Enhancing CTL responses to melanoma cell vaccines in vivo: synergistic increases obtained using IFNgamma primed and IFNbeta treated B7-1+ B16-F10 melanoma cells. Immunol Cell Biol 2003; 81: 459-71.
172. Lotem M, Shiloni E, Pappo I, Drize O, Hamburger T, Weitzen R, et al. Interleukin-2 improves tumour response to DNP-modified autologous vaccine for the treatment of metastatic malignant melanoma. Br J Cancer 2004; 90: 773-80.
173. Boyaka PN, Tafaro A, Fischer R, Fujihashi K, Jirillo E, McGhee JR. Therapeutic manipulation of the immune system: enhancement of innate and adaptive mucosal immunity. Curr Pharm Design 2003; 9(24): 1965-72.
174. Foster AE, Forrester K, Li Y. C, Gottlieb DJ. Ex-vivo uses and applications of cytokines for adoptive immunotherapy in cancer. Curr Pharm Design 2004; 10(11): 1207-20.
175. Rengifo-Cam W, Singh P. Role of progastrins and gastrins and their receptors in GI and pancreatic cancers: targets for treatment. Curr Pharm Design 2004; 10(19): 2345-58.